Biogen Inc. expects to begin shipping the company’s newly approved Alzheimer’s drug Aduhelm in about two weeks and has prepared more than 900 healthcare centers for the intravenous infusion treatment.
The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.
